InvestorsHub Logo
Followers 154
Posts 2652
Boards Moderated 0
Alias Born 01/29/2004

Re: nidan7500 post# 167510

Wednesday, 10/03/2018 2:24:39 PM

Wednesday, October 03, 2018 2:24:39 PM

Post# of 463611
No Alternative


Why did the FDA continue/or allow the continuance of Amyloid Thesis based trials for decades, long after any child could see they were going nowhere? (see 99.6% failure w/> 1000 attempts over 20+ years).


Why? No other option was available. First, the exact, root, underlying cause of Alzheimer’s was not known (nor even completely recognized by the medical community today). It was presumed to be incidentally idiopathic with age. Happened because people got old, and with that, brain function declines. In the case of Alzheimer’s, cerebral aging was simply rapid and severe.

What, then, to fix? Waste protein deposits, beta-amyloids and tau tangles could be microscopically detected. They provided detectible chemical targets for therapy. The presumption (probably accurate) was that if the waste protein accumulations could be either prevented or completely removed, brain functions would be restored or preserved.

Nice idea. But so far, after billions of dollars have been spent on any number of chemotherapeutic approaches, every one has failed. Simply, pulling off and digesting the waste protein accumulations concomitantly disrupts other normal brain chemistries. Side effects inevitably too great; therapeutic outcomes too meek. The realization of failure with the waste accumulation therapeutic target is finally in place.

Frankly, the FDA had to let the waste protein approaches go forward. There was nothing else but the existing acetylcholinesterase inhibitors to treat Alzheimer’s. Sadly, those drugs only slow, for a period, the otherwise lethal progression of the disease.

Because it goes against what physicians and researchers learned from their vaunted med-school professors, researchers yet are slow to embrace the Anavex explanation of Alzheimer’s disease; or it’s unique therapy for such, with the proprietary sigma-1 receptor agonists.

All of that will change rather dramatically when positive results appear in the upcoming Anavex 2-73 trial in Australia. Last-century perspectives on Alzheimer’s causes and treatments will necessarily be discarded.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News